Atherothrombogenic Risk Modulation by n-3 Fatty Acids Was not Associated with Changes in Homocysteine in Subjects with Combined Hyperlipidaemia

H. Grundt; D. W. T. Nilsen; Ø. Hetland; M. A. Mansoor; T. Aarsland; L. Woie

doi:10.1055/s-0037-1614524

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 81(04): 561-565
DOI: 10.1055/s-0037-1614524

Rapid Communication

Schattauer GmbH

Atherothrombogenic Risk Modulation by n-3 Fatty Acids Was not Associated with Changes in Homocysteine in Subjects with Combined Hyperlipidaemia

H. Grundt

¹From the Departments of Medicine, Stavanger, Norway

,

D. W. T. Nilsen

¹From the Departments of Medicine, Stavanger, Norway

,

Ø. Hetland

²Clinical Chemistry, Central Hospital in Rogaland, Stavanger, Norway

,

M. A. Mansoor

²Clinical Chemistry, Central Hospital in Rogaland, Stavanger, Norway

,

T. Aarsland

³Hjertelaget Research Foundation, Stavanger, Norway

,

L. Woie

¹From the Departments of Medicine, Stavanger, Norway

› Author Affiliations

Abstract

Summary

Favourable effects of n-3 fatty acids on the atherogenic risk profile were recently demonstrated in subjects with combined (type IIb) hyperlipidaemia, not responding to a therapeutic diet.

Re-examination of a previous patient material was performed to assess the influence of n-3 fatty acids on homocysteine and several coagulation factors.

Subjects were randomly allocated to receive either a concentrated compound of 85% eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) (n = 28), or corn oil (n = 29), in a daily dose of 4 g for 12 weeks. The intervention was double-blind.

Homocysteine remained unchanged in both groups after 12-week treatment. N-3 fatty acids supplementation did not affect the levels of fibrinogen, coagulation factor VII or tissue factor pathway inhibitor (TFPI), while plasminogen activator inhibitor (PAI) increased significantly (Student’s t-test; p <0.05). Total blood platelets were significantly reduced in subjects receiving n-3 fatty acids (Student’s t-test; p <0.05), whereas bleeding times increased non-significantly.

Full Text

References

References
1 Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
2 Kang S-S, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-98.
3 Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-17.
4 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocyteine as a risk factor for vascular disease: probable benefits of increasing folic acids intakes. JAMA 1995; 274: 1049-57.
5 Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
6 Selhub J, Jacques PF, Bostom AG, D’Agostino RB, Wilson PWF, Belanger AJ, O’Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
7 Malinow MR, Stampfer MJ. Role of plasma homocyst(e)ine in arterial occlusive disease. Clin Chem 1994; 40: 857-58.
8 Heijer MD, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
9 Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal AA, Nordrehaug JE, Ueland PM, Kvåle G. Total plasma homocysteine and cardiovascular risk profile. JAMA 1995; 274: 1526-33.
10 Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith I, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-6.
11 Kinsella JE, Lokesh B, Stone RA. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. Am J Clin Nutr 1990; 52: 1-28.
12 Høstmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K. Fish oil and plasma fibrinogen. BMJ 1988; 297: 180-1.
13 Olszewski AO, Kilmer S, Cully MC. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993; 4: 53-60.
14 Grundt H, Nilsen DWT Hetland Ø, Aarsland T, Baksaas I, Grande T, Woie L. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J Intern Med 1995; 237: 249-59.
15 Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-59.
16 Hamsten A, Wiman B, Faire UD, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
17 Andersen P, Nilsen DWT, Beckmann SL, Holme I, Hjermann I. Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. Acta Med Scand 1988; 223: 499-506.
18 Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cyteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992; 200: 218-29.
19 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
20 Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoprotein from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-95.
21 Møller JM, Nielsen GL, Ekelund S, Schmidt EB, Dyerberg J. Homocysteine in Greenland Inuits. Thromb Res 1997; 86: 333-5.
22 Holdt B, Korten G, Knippel M, Lehmann JK, Claus R, Holtz M, Hausmann S. Increased serum levels of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int 1996; 16 (01) Suppl S246-9.
23 Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in ischemic heart disease. Atherosclerosis 1988; 69: 109-13.
24 Lipoprotein (a). Editorials. Lancet 1991; 337: 397-8.
25 Tonstad S. Correlates of plasma total homocysteine in patients with hyperlipidaemia. Eur J Clin Invest 1997; 27: 1025-9.
26 Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-7.
27 McCully KS. Homocysteine metabolism in scurvy, growth and arteriosclerosis. Nature 1971; 231: 391-2.
28 Gey KF. On the antioxidant hypothesis with regard to arteriosclerosis. Bibl Nutr Dieta 1986; 37: 53-91.
29 Schmidt EB, Varming K, Ernst E, Madsen P, Dyerberg J. Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thromb Haemost 1990; 63: 1-5.
30 Sandset PM, Abildgaard U. Extrinsic pathway inhibitor. The key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39.
31 Nilsen DWT, Dalaker K, Nordøy A, Østerud B, Ingebretsen OC, Lyngmo V, Almdahl S, Vaage J, Rasmussen K. Influence of a concentrated ethyl-ester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery. Thromb Haemost 1991; 66: 195-201.
32 Goodnight SH, Harris WS, Connor WE. The effects of dietary ω-3 fatty acids on platelet composition and function in man: A prospective, controlled study. Blood 1981; 58: 880-5.
33 Hamazaki T, Nakazawa R, Tateno S, Shishido H, Isoda K, Hattori T, Yoshida T, Fujita T, Yano S, Kumagai A. Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients. Kidney Int 1984; 26: 81-4.
34 Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996; 121: 231-43.
35 Harpel PC, Zhang X, Borth W. Homocysteine and Hemostasis: Pathogenetic Mechanisms Predisposing to Thrombosis. J Nutr 1996; 126: 1285S-89S.